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ABSTRACT
Objective: The objective of the present study was preparation and evaluation of lornoxicam microsponges to prolong their drug release up to 12 h for 
effective osteoarthritis, rheumatoid arthritis, and acute lumbar-sciatica therapy.
Methods: Lornoxicam microsponges were prepared by the quasi-emulsion solvent diffusion technique using different concentrations of polymers 
such as Eudragit RS 100 and Eudragit RSPO in ethanol and dichloromethane organic solvent mixture. Microsponges were evaluated for their particle 
size, percentage yield, entrapment efficiency, scanning electron microscopy (SEM), and in vitro drug release studies.
Results: The percentage yield, entrapment efficiency, average particle size, and in vitro drug release for optimized formulation F12 were found to be 
70.23% w/w, 81.34% w/w, 172.72 µm, and 96.64% up to 8 h, respectively. From SEM, it was observed that microsponges were found to be spherical in 
shape with rough surface texture. The formulation F12 shows zero-order release kinetics with an r2 value of 0.961 and the value of Korsmeyer–Peppas 
model was found to be 0.792; it follows super case II non-Fickian diffusion. The in vitro drug release studies showed that formulations comprised 
varying concentrations of Eudragit RSPO in higher proportion exhibited much-retarded drug release as compared to formulations comprised a higher 
proportion of varying concentrations of Eudragit RS 100.
Conclusion: Among all the formulations F12 shows better results, which are released more than 80% of the drug release within 8 h; hence, it is 
optimized. These developed microsponges are releasing the drug for a longer period, which will be effective for osteoarthritis, rheumatoid arthritis, 
and acute lumbar sciatica therapy.
Keywords: Lornoxicam, Microsponges, Quasi-emulsion solvent diffusion method, Eudragit RS 100, Eudragit RSPO.
INTRODUCTION
Microsponge delivery system is porous, polymeric microspheres that 
can entrap broad range of active ingredients and release the drug 
over an extended period of time [1]. The microsponge technology was 
developed by won in 1987 [2]. Microsponges are porous microspheres, 
biologically inert particles that are made of synthetic polymers and the 
particles serve to protect the entrapped drug compound from physical 
and environmental degradation [3]. They are tiny sponge-like spherical 
particles that consist of innumerable of interconnecting voids within 
a non-collapsible structure with a large porous surface. The size of 
the microsponges usually ranges from 5 to 300 μm in diameter, and 
a typical 25 μm sphere can have as many as 2,50,000 pores and an 
internal pore structure equivalent to 10 ft in length, providing a total 
pore volume of about 1 ml/g [4]. They are used as a carrier system 
since they have the capacity to entrap a wide range of actives in their 
non-collapsible structures with porous surface, through which active 
ingredients are released in a controlled manner. These microsponges 
entrapped with the drug can be incorporated into formulations such as 
tablets, capsules, creams, gel, lotions, and powders [5]. This technology 
also offers entrapment of active pharmaceutical ingredients, increased 
elegance, improved stability enhanced formulation flexibility, and 
reduced side effects [6].
Lornoxicam is a nonsteroidal anti-inflammatory drug of the oxicam 
class with analgesic, anti-inflammatory, and antipyretic properties. 
Lornoxicam formulations are available in oral and parenteral 
formulations. Lornoxicam is a yellow or slightly yellowish powder. 
It is slightly soluble in water, soluble in methanol and ethanol. Its 
release from the sustain release dosage form is limited to the lower 
gastrointestinal tract which consequently leads to a delayed onset of 
its analgesic action. It is prescribed for osteoarthritis, rheumatoid 
arthritis, acute lumbar sciatica conditions, and for post-operative pain 
management. Lornoxicam is given in doses of 8–16 mg daily by mouth 
for the treatment of pain. Doses above 8 mg should be given in divided 
doses. Similar doses may be given by intravenous or intramuscular 
injection, although in rare cases the maximum initial daily dose may be 
increased to 24 mg, treatment by injection should be limited to 2 days 
[7-9]. The aim of this study was to prepare sustained release lornoxicam 
microsponge based capsules using polymer such as Eudragit RS 100 
and Eudragit RSPO with reduced frequency and side effects, for effective 
osteoarthritis, rheumatoid arthritis, and acute lumbar sciatica therapy. 
A comparative study of all the formulations prepared by quasi-emulsion 
solvent diffusion method was aimed, and the effects of drug-polymer 
ratios and external phase compositions used on release kinetics have 
also been studied (Fig. 1).
MATERIALS AND METHODS
Materials
Lornoxicam was procured from Pradeep Kumar Pharma Pvt., Ltd. 
(Mumbai - India), Eudragit RS 100 and Eudragit RSPO are gifted by 
Evonik Pharma, Mumbai, India. Methanol, ethanol, polyvinyl alcohol 
(PVA), polyethylene glycol 400, propylene glycol, and potassium 
dihydrogen orthophosphate were purchased from LOBA Chemie Pvt., 
Ltd., Mumbai, India.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Methods
Procedure for drug and excipients compatibility by Fourier-
transform infrared (FTIR) studies
The FTIR spectra of samples of lornoxicam, Eudragit RS 100, Eudragit 
RSPO, physical mixture of drug and Eudragit RS 100, drug and Eudragit 
RSPO and drug, Eudragit RS 100 and Eudragit RSPO were recorded by 
using FTIR spectrometer. Spectra between 4000 and 400 cm-1 of the 
drug, a before mentioned polymers and for drug-polymers powder 
mixtures were recorded using FTIR spectrophotometer (Bruker, 
ATR, version1.2.4) using KBr pellet technique. In this ATR sampling 
technique, solid samples to be analyzed should free from moisture. 
Samples were dried by placing in the oven for 20 min at 40°C. One 
spatula of dried sample placed into mortar and pestle and properly 
grained. The prepared sample was placed on the crystal of ATR for 
recording spectrum [10].
Formulation of lornoxicam microsponges
All the formulations were prepared by the quasi-emulsion solvent 
diffusion technique using the polymers Eudragit RS 100 and Eudragit 
RSPO and plasticizers polyethylene glycol 400 and propylene glycol. 
Drug, polymer, and plasticizer were dissolved in a mixture of ethanol 
and dichloromethane and then sonicated for 10 min. This solution was 
poured drop by drop with a syringe into 1000 ml beaker containing 
0.75% w/v PVA solution, maintained at a temperature of 30–40°C with 
stirring at 1000–1200 rpm speed for 5 h to allow the volatile solvent for 
evaporation. The formulated microsponges were filtered, washed with 
distilled water and dried at 40°C [5,6,11]. The various formulations 
prepared using different polymers and plasticizers with different ratios 
are shown in Table 1.
Evaluation of lornoxicam microsponges
Scanning electron microscopy (SEM) studies
The lornoxicam microsponges were observed under a SEM. The 
instrument used in this study was Hitachi S-3700N, Japan. The 
microsponges were mounted directly on the SEM sample stub, using 
double-sided sticking tape and coated with a gold film (thickness 180–
200 nm) under reduced pressure.
Particle size analysis
The particle size was measured using an optical microscope, and 
the mean particle size was calculated by measuring 100 particles 
with the help of a calibrated ocular micrometer. The slide containing 
microsponges were mounted on the stage of the microscope and 
diameter of at least 100 particles was measured using a calibrated 
optical micrometer.
Percentage production yield
The production yield of the microsponges was determined by 
calculating accurately the initial weight of raw materials and the last 
weight of microsponges obtained, and their percentage yield (w/w) 
was determined using below equation [12].
Yield
Actual weight of the product




Percentage of unentrapped drug
Formulated microsponges were filtered from PVA solution. Filtered 
microsponges were washed thoroughly with 0.75% w/v PVA solution, 
and washings were added to the above filtrate. 5 ml was taken from 
this mixture of filtrate and washings, and centrifuged for 10 min 
and filtered. Filtered sample was suitably diluted with 0.75% w/v 
PVA solution and analyzed spectrophotometrically at 354 nm using 
ultraviolet (UV)-Vis spectrophotometer. Percentage of the unentrapped 
drug was calculated [13].
Percentage of
unentrapped drug %









Microsponges equivalent to 16 mg of pure drug was crushed, powdered 
and was taken in 100 ml volumetric flask. To this, 80 ml of methanol was 
added and shaken for 1 h on a mechanical shaker and then sonicated 
for 5 min to complete removal of lornoxicam from microspheres. After 
sonication, volume was made up to the mark with methanol. This 
solution was centrifuged and filtered. Filtered sample was suitably 
diluted with methanol and analyzed spectrophotometrically at 353 nm 
using UV-VIS spectrophotometer. Entrapment efficiency was calculated 
as follows [14,15].
Entrapment efficiency




amount of drug used
for microsponges
×100
In vitro drug release studies
Procedure
In vitro, drug release studies were carried out using USP type II 
apparatus at 100 rpm. Microsponges equivalent to 16 mg of pure 
drug was added to 900 ml of pH6.8 phosphate buffer which is used as 
the dissolution medium. The temperature of the dissolution medium 
was maintained at 37±0.5°C. An aliquot (5 ml) of dissolution medium 
was withdrawn at specific time intervals up to 12 h, filtered and 
suitably diluted before spectrophotometric analysis. Sink conditions 
were maintained by replenishing the medium with an equal amount 
(5 ml) of pH6.8 phosphate buffer. The absorbance of the sample was 
measured at 357 nm by UV-Visible spectrophotometer [16]. The 
concentration of lornoxicam in test samples was calculated using 
calibration curve. Six samples were run for each formulation in pH 6.8 
phosphate buffer.
Table 1: Formula of lornoxicam microsponges
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12
Drug: polymer ratio 1:1 1:0.75 1:0.5 1:0.5 1:0.5 1:0.5 1:1 1:0.75 1:0.5 1:0.5 1:0.5 1:0.5
Lornoxicam (mg) 500 500 500 500 500 500 500 500 500 500 500 500
Eudragit RS 100 (mg) - - - - - - 500 325 250 250 250 250
Eudragit RSPO (mg) 500 325 250 250 250 250 - - - - - -
PEG plasticizer (ml) 0.5 0.5 - 0.25 - 0.5 0.5 0.5 - 0.25 - 0.5
PG plasticizer (ml) - - 0.25 0.25 0.5 - - - 0.25 - 0.5 -
0.75% w/v PVA solution (ml) 500 500 500 500 500 500 500 500 500 500 500 500
Ethanol (ml) 10 10 10 10 10 10 10 10 10 10 10 10
Dichloromethane (ml) 10 10 10 10 10 10 10 10 10 10 10 10
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RESULTS AND DISCUSSION
Drug and excipient compatibility studies by FTIR
FTIR spectrum of lornoxicam was recorded, and spectral interpretation 
was done. The characteristics IR absorption peaks of lornoxicam 
C=O 1 amide stretching at 1641.30 cm-1, N-H 2o amide stretching at 
3122.62 cm−1, C-Cl aromatic stretching at 670.15 cm−1, Thiazide SO2 
at 1354.60 cm−1, C-H aromatic stretching at 3068.73 cm−1, and O-H 
stretching at 3393.35 cm−1 were there in drug sample spectrum, which 
confirmed the purity of lornoxicam.
Compatibility study using FTIR was carried out to ensure any possible 
interaction between drug and Eudragit RS100 and Eudragit RSPO used. 
FTIR spectroscopic study results revealed no any new peak appearance 
or disappearance of existing peaks, discarding any chemical interaction 
probability among drug and polymers used. The characteristic C=O 1o 
amide stretching vibration at 1640.91 cm-1, N-H 2o amide stretching 
at 3123.29, C-Cl aromatic stretching at 670.05 cm-1, Thiazide SO2 
at 1354.71 cm-1, C-H aromatic stretching at 3068.71 cm-1, and O-H 
stretching at 3393.53 cm-1 peaks of lornoxicam were present in the 
physical mixture of drug and polymers. Thus, FTIR spectroscopy results 
showed that lornoxicam was compatible with selected polymers (Fig. 2).
SEM
Morphology of prepared microsponges was discovered by SEM analysis. 
SEM image of optimized formulation (F12) of lornoxicam microsponges 
shown in Fig. 3. SEM results indicated that microsponges formed were 
highly porous, spherical in shape with rough surface texture and tiny 
particles are adhered on the porous outer surface. Pores were induced 
by diffusion of solvent from the surface of microsponges.
Percentage yield, percentage of unentrapped drug, percentage 
entrapment efficiency, and particle size studies of lornoxicam 
microsponges
The percentage yield of all formulations was carried out and was 
found within the range between 69.58% and 75.35%. Percentage of 
the unentrapped drug was found to be 24.06%–30.35%. Entrapment 
efficiency was found to be 62.24%–70.34%. The mean particle size 
of the microsponges significantly increased with increase in polymer 
concentration. The reason may be due to the viscosity of medium which 
increases as the polymer concentration increases. This may be resulting 
in the formation of larger particles. The particle size of prepared 
microsponges was observed in the range of 172.72–234.44 µm. The 
sizes of microsponges affect the encapsulation efficiency and the release 
rate of the drug. It was observed that as the ratio of drug to polymer 
was increased, the encapsulation efficiency was decreased. This could 
probably be due to the fact that in high drug to polymer ratio, the 
amount of polymer available per microsponge was comparatively less. 
Probably in high drug-polymer ratios less polymer amounts surround 
the drug and reducing the thickness of polymer wall and microsponges 
with smaller size were obtained (Table 2).
In vitro drug release
In vitro, drug release studies were performed in pH 6.8 phosphate 
buffer for 12 h. The cumulative percentage of drug release of prepared 
formulations was found to be in the following order: F12> F11> F6> 
F5> F10> F9> F4> F3> F8> F7>F2>F1. The percentage drug release 
of formulations F1, F2, F3, F4, F5, F6, F7, F8, F9, and F10 was found 
to be 61.21%, 65.61%, 80.68%, 83.25%, 92.57%, 95.09%, 73.46%, 
86.65%, and 89.17%, in 12 h respectively. The percentage drug release 
of formulation F11 was found to be 95.47% in 10 h. Formulation F12 
showed high release, 95.47% in 8 h. This could be due to smaller 
microsponges are formed at a lower polymer concentration and have a 
large surface area exposed to dissolution medium, giving rise to faster 
drug release. Hence, it is considered as an optimized formulation.
Results indicate that proportion of polymers in the formulation was 
the key factor governing the release of drug from microsponges. As the 
concentration of polymer increased, there was an increase in particle 
size and diffusional path length. This may decrease the overall drug 
release from the polymer matrix. Formulations comprised Eudragit 
RSPO in higher proportion exhibited much-retarded drug release 
as compared to formulations comprised Eudragit RS 100 in higher 
proportion. The drug release profile from microsponges for all the 
formulations is shown in Figs. 4-7 and Table 3.
Release of lornoxicam from the microsponges for the optimized 
formulation F12 was found to follow zero-order kinetics (correlation 
Fig. 1: Lornoxicam
Fig. 2: Fourier-transform infrared Spectras of (a) Lornoxicam, 
(b) Eudragit RSPO, (c) Eudragit RS 100,  (d) physical mixture 
of lornoxicam and Eudragit RSPO, (e) physical mixture of 
lornoxicam and Eudragit RS 100, (f) physical mixture of 
lornoxicam, Eudragit RS 100, and Eudragit RSPO
Fig. 3: Scanning electron microscopy photograph of optimised 
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coefficient, r2 value 0.961). Higuchi plot showed an r2 value of 0.971 for 
optimized formulation F12 suggesting that the diffusion plays an important 
role in the controlled release. The data were fitted to Korsmeyer–Peppas 
equation; the value of diffusion exponent “n” for optimized formulation 
F12 is 1.731, indicated that the drug release follows super case II diffusion.
CONCLUSION
Microsponges of lornoxicam were prepared by the quasi-emulsion 
solvent diffusion method using polymers such as Eudragit RS 100 and 
Eudragit RSPO. As the polymer concentration is increasing, the particle 
size of microsponges was increased, and the drug release was decreased. 
Among all the formulations, F12 shows better results, which are released 
more than 80% of the drug release within 8 h. Hence, lornoxicam loaded 
microsponges prepared by this quasi-emulsion solvent diffusion method 
are potential for prolong the release of the drug, which will be effective for 
osteoarthritis, rheumatoid arthritis, and acute lumbar sciatica therapy.
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Table 2: Percentage yield, Percentage of unentrapped drug, percentage entrapment efficiency, and particle size of lornoxicam 
microsponges
Formulation Percentage yield  
(%w/w)*
Percentage of  
unentrapped drug (%w/w)*
Percentage of Entrapment 
efficiency (%w/w)*
Particle size  
(µm)*
F1 75.08±0.965 30.35±1.036 62.24±1.729 234.44±0.965
F2 72.21±1.034 30.27±1.873 63.50±1.137 221.24±1.211
F3 69.58±0.928 29.23±2.589 64.41±2.645 208.44±1.325
F4 70.16±2.147 29.54±2.764 65.29±2.749 203.24±2.564
F5 71.43±2.138 28.48±1.773 69.65±1.211 189.78±3.034
F6 73.12±1.917 28.82±1.248 67.75±1.765 187.96±3.252
F7 75.35±1.346 28.57±2.432 67.75±1.629 218.54±2.954
F8 73.92±3.270 27.34±2.032 68.27±1.375 214.26±2.342
F9 71.28±2.164 27.83±1.258 68.57±2.125 193.2±2.456
F10 73.65±1.560 26.67±1.045 69.21±1.432 190.5±3.348
F11 70.45±1.317 26.19±2.845 69.68±2.327 175.1±3.587
F12 70.23±1.305 24.06±2.035 70.34±2.034 172.72±3.623
*(n=3), (average±SD)




Zero‑order (r2) First‑order (r2) Higuchi Model (r2) Korsmayer–Peppas
r2 value n Value
F1 0.981 0.928 0.881 0.954 1.408
F2 0.991 0.948 0.912 0.927 1.410
F3 0.995 0.966 0.970 0.895 1.487
F4 0.991 0.968 0.949 0.880 1.489
F5 0.970 0.970 0.978 0.880 1.504
F6 0.961 0.961 0.983 0.840 1.487
F7 0.994 0.963 0.935 0.817 1.415
F8 0.994 0.971 0.937 0.905 1.442
F9 0.986 0.970 0.958 0.893 1.509
F10 0.976 0.975 0.970 0.858 1.511
F11 0.973 0.906 0.980 0.809 1.558
F12 0.961 0.807 0.971 0.792 1.731
Fig. 4: Zero-order release profile of lornoxicam microsponges 
(F1‑F12) (n=6)
Fig. 5: First-order drug release profile of lornoxicam 
microsponges (F1‑F12) (n=6)
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